Ocrelizumab and weight-loss drugs for MS
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Immune system & allergy clinical trials.
This study looks at combining ocrelizumab (an MS treatment) with GLP-1 agonists (like Ozempic, used for weight management) in people with MS. It aims to see if the combination is safe and beneficial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with multiple sclerosis (any type) by a neurologist.
- Your body mass index (BMI) is 24 or higher.
- You have taken at least one dose of ocrelizumab before joining the study.
- You can walk without major assistance (EDSS less than 7).
- You have an MRI that confirms your MS diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This trial tests if a GLP-1 receptor agonist can help people with multiple sclerosis who have a high BMI. It may reduce inflammation and improve health.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
This study looks at whether Ocrelizumab, an MS medication you may already be taking, can help improve fatigue and thinking problems (like memory and focus) in veterans with MS. It involves checking your energy levels and mental abilities over time.
This study looks at how ocrelizumab treatment affects a nerve health marker called neurofilament light chain (NfL) and how satisfied you are with the treatment. It may help doctors understand if this medicine works well for people with multiple sclerosis.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.